SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
SeaStar Medical Holding (Nasdaq: ICU), a commercial-stage healthcare company specializing in treatments for critically ill patients with organ failure, has scheduled its fourth quarter and year-end 2024 financial results announcement for March 27, 2025, after market close.
The company will host a webcast and conference call to discuss the results and business progress. A replay will be available until April 3, 2025, accessible via webcast or by calling 1 (609) 800-9909.
SeaStar Medical Holding (Nasdaq: ICU), un'azienda sanitaria in fase commerciale specializzata nel trattamento di pazienti gravemente malati con insufficienza d'organo, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'anno 2024 per il 27 marzo 2025, dopo la chiusura del mercato.
L'azienda ospiterà un webcast e una conferenza telefonica per discutere i risultati e i progressi aziendali. Una registrazione sarà disponibile fino al 3 aprile 2025, accessibile tramite webcast o chiamando il numero 1 (609) 800-9909.
SeaStar Medical Holding (Nasdaq: ICU), una empresa de atención médica en etapa comercial especializada en tratamientos para pacientes críticamente enfermos con fallo orgánico, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año 2024 para el 27 de marzo de 2025, después del cierre del mercado.
La empresa llevará a cabo un webcast y una llamada de conferencia para discutir los resultados y el progreso del negocio. Una repetición estará disponible hasta el 3 de abril de 2025, accesible a través del webcast o llamando al 1 (609) 800-9909.
SeaStar Medical Holding (Nasdaq: ICU), 중증 환자의 장기 부전 치료에 전문화된 상업 단계의 의료 회사가 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 27일 시장 마감 후로 예정했습니다.
회사는 결과 및 사업 진행 상황을 논의하기 위해 웹캐스트 및 컨퍼런스 콜을 개최할 것입니다. 재생은 2025년 4월 3일까지 이용 가능하며, 웹캐스트를 통해 또는 1 (609) 800-9909로 전화하여 접근할 수 있습니다.
SeaStar Medical Holding (Nasdaq: ICU), une entreprise de santé en phase commerciale spécialisée dans les traitements pour les patients gravement malades souffrant d'insuffisance organique, a prévu l'annonce de ses résultats financiers du quatrième trimestre et de l'année 2024 pour le 27 mars 2025, après la fermeture du marché.
L'entreprise organisera un webcast et une conférence téléphonique pour discuter des résultats et des progrès de l'entreprise. Un enregistrement sera disponible jusqu'au 3 avril 2025, accessible via le webcast ou en appelant le 1 (609) 800-9909.
SeaStar Medical Holding (Nasdaq: ICU), ein Unternehmen im kommerziellen Gesundheitsbereich, das sich auf Behandlungen für kritisch kranke Patienten mit Organversagen spezialisiert hat, hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierte Quartal und das Jahr 2024 auf den 27. März 2025, nach Börsenschluss, festgelegt.
Das Unternehmen wird ein Webcast und eine Telefonkonferenz veranstalten, um die Ergebnisse und den Fortschritt des Unternehmens zu besprechen. Eine Wiederholung wird bis zum 3. April 2025 verfügbar sein, die über den Webcast oder unter der Nummer 1 (609) 800-9909 erreichbar ist.
- None.
- None.
DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2024 financial results after market close on Thursday, March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress.
| Date/Time: | Thursday, March 27, at 4:30 p.m. ET / 1:30 p.m. PT |
| Webcast: | The live webcast and replay can be found here. |
| Conference ID: | 2078693 |
| Dial-in numbers: | 1 (800) 715-9871 within the U.S. |
| 1 (646) 307-1963 from outside the U.S. | |
A replay of the call will be available after 7:30 pm ET and can be accessed as follows:
- The webcast replay is available here.
- The call replay number is 1 (609) 800-9909 and will be available through April 3, 2025.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for four therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com
FAQ
When will SeaStar Medical (ICU) release its Q4 and full-year 2024 earnings?
How can investors access SeaStar Medical's (ICU) Q4 2024 earnings call replay?
Until what date will SeaStar Medical's (ICU) Q4 2024 earnings call replay be available?
What is SeaStar Medical's (ICU) primary business focus?
